Skip to main content

Table 4 Competing risks regression for the association between increasing RS and iLRR for patients treated with adjuvant hormone therapy without chemotherapy

From: Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer

Hormonal therapy without chemotherapy

Competing risk regression for iLRR

60-month cumulative incidence of iLRR (95% CI)

HR (95% CI)

Ptrend

RS < 18

1.0 (reference)

0.02

1.2% (0.5–2.8%)

RS 18–24

1.66 (0.59–4.66)

 

3.7% (1.5–7.7%)

RS 25–30

3.59 (0.78–16.6)

 

7.3% (1.0–22.7%)

RS ≥31

7.05 (0.97–51.3)

 

33.3% (0.9–77.4%)

  1. CI confidence interval, HR hazard ratio, iLRR isolated locoregional recurrence, RS recurrence score